PROCEPT BioRobotics to Present at Upcoming 2024 Wells Fargo Healthcare Conference on September 4, 2024
PROCEPT BioRobotics (Nasdaq: PRCT), a surgical robotics company specializing in urology solutions, has announced its participation in the 2024 Wells Fargo Healthcare Conference in Boston.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PROCEPT BioRobotics (Nasdaq: PRCT), a surgical robotics company specializing in urology solutions, has announced its participation in the 2024 Wells Fargo Healthcare Conference in Boston. The company's management team is scheduled to present on Wednesday, September 4, 2024, at 1:30 p.m. Eastern Time.
Investors and interested parties can access a live webcast of the presentation through the company's website at https://ir.procept-biorobotics.com. The webcast will also be archived for at least 90 days after the event, allowing for later viewing. This presentation offers an opportunity for PROCEPT BioRobotics to showcase its innovative urological solutions and connect with healthcare industry professionals and investors.
Details
News Market Reaction – PRCT
The recorded move for PRCT in the trading session of this news was -1.65%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN JOSE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Wells Fargo Healthcare Conference in Boston, Massachusetts. Management is scheduled to present on Wednesday, September 4 at 1:30 p.m. Eastern Time.
A live webcast of each event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The HYDROSTM Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.